Use of tyrosine kinase inhibitors for treating multiple...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/00 (2006.01) A61K 31/015 (2006.01) A61K 31/095 (2006.01) A61K 31/40 (2006.01) A61K 31/403 (2006.01) A61K 31/404 (2006.01) A61K 31/415 (2006.01) A61K 31/4709 (2006.01) A61K 31/495 (2006.01) A61K 31/498 (2006.01) A61K 31/50 (2006.01) A61K 31/505 (2006.01) A61K 31/506 (2006.01) A61K 31/517 (2006.01) A61K 31/519 (2006.01) A61K 31/66 (2006.01) A61K 45/06 (2006.01) A61P 25/28 (2006.01)

Patent

CA 2452167

The present invention relates to a method for treating Multiple Sclerosis (MS) comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

La présente invention concerne une technique de traitement de la sclérose en plaques qui consiste à administrer un inhibiteur de tyrosine kinase à une personne atteinte de cette maladie, plus particulièrement un inhibiteur puissant de kinase de type c-kit. Cet inhibiteur n'est de préférence pas capable de favoriser la mort des cellules dépendantes de l'interleukine 3 (IL-3) cultivées en présence de IL-3.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of tyrosine kinase inhibitors for treating multiple... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of tyrosine kinase inhibitors for treating multiple..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tyrosine kinase inhibitors for treating multiple... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1860885

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.